← All stocks

Septerna, Inc.

SEPN Net buying
CIK 0001984086 #2087 in the set updated 17 Sep 2026
Bought (120 mo)
$93.97M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$76.05M
$7.40M on a plan · $5.14M straight out of an exercise
Sold at will
$63.52M
3 of 27 sales
Net
+$17.92M
+$30.46M against sales at will

By person

10 insiders · 51 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
Director
$75.06M (2)
$63.45M (2)
+$11.61M
725,443
1.55%
$27.44M
Third Rock Ventures VI, L.P. entity
10% owner
$6.28M (3)
+$6.28M
4,211,659
9.02%
$159.31M
+33.6%
Third Rock Ventures V, L.P. entity
10% owner
$11.70M (2)
$7.40M (2) scheduled
+$4.30M
9,220,847
19.75%
$348.80M
+1,113%
Shaikhly Samira
Chief People Officer
$2.80M (8) scheduled
−$2.80M
793
0.0017%
$30.00K
0.0%
Bhatt Elizabeth
President and COO
$1.45M (7) scheduled
−$1.45M
174,209
0.3732%
$6.59M
0.0%
Long Daniel D.
SVP, Drug Discovery
$951.33K (8) scheduled
−$951.33K
96,412
0.2066%
$3.65M
−3.5%
Ezekowitz Alan
Director
$608.20K (4)
+$608.20K
117,420
0.2516%
$4.44M
+574.1%
Labrucherie Gil M
Chief Financial Officer
$229.16K (5)
+$229.16K
40,000
0.0857%
$1.51M
Finer Jeffrey
Chief Executive Officer
$96.96K (3)
+$96.96K
826,907
1.77%
$31.28M
+9.5%
Klein Uwe
SVP, Biological Sciences
23,008
0.0493%
$870.33K
Insider
Date
Role
Action
Shares
Price
Amount
Long Daniel D.
1 Sep 2026
SVP, Drug Discovery
Sold after exercise
3,333
$37.83
$126.08K
Bhatt Elizabeth
11 Aug 2026
President and COO
Sold after exercise
25,000
$44.00
$1.10M
Long Daniel D.
3 Aug 2026
SVP, Drug Discovery
Sold after exercise
2,334
$34.68
$80.94K
Long Daniel D.
3 Aug 2026
SVP, Drug Discovery
Sold after exercise
1,000
$33.98
$33.98K
Bhatt Elizabeth
15 Jul 2026
President and COO
Sold after exercise
4,000
$33.99
$135.97K
Long Daniel D.
1 Jul 2026
SVP, Drug Discovery
Sold after exercise
1,233
$34.81
$42.93K
Long Daniel D.
1 Jul 2026
SVP, Drug Discovery
Sold after exercise
2,100
$34.10
$71.60K
Shaikhly Samira
29 Jun 2026
Chief People Officer
Sold after exercise
2,178
$35.18
$76.62K
Long Daniel D.
22 Jun 2026
SVP, Drug Discovery
Sold after exercise
7,000
$35.97
$251.78K
Long Daniel D.
22 Jun 2026
SVP, Drug Discovery
Sold after exercise
8,000
$35.10
$280.80K
Shaikhly Samira
12 Jun 2026
Chief People Officer
Sold after exercise
6,250
$35.08
$219.22K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
2,889
$29.66
$85.70K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
1,346
$28.79
$38.76K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
1,700
$27.78
$47.23K
Shaikhly Samira
26 May 2026
Chief People Officer
Sold after exercise
11,798
$30.06
$354.66K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
326
$25.86
$8.43K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
1,101
$25.24
$27.79K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
2,573
$23.76
$61.12K
Shaikhly Samira
2 Mar 2026
Chief People Officer
Sold after exercise
66,363
$28.14
$1.87M
Shaikhly Samira
2 Mar 2026
Chief People Officer
Sold after exercise
4,090
$27.51
$112.50K
Bhatt Elizabeth
18 Feb 2026
President and COO
Sold after exercise
1,800
$29.58
$53.25K
Bhatt Elizabeth
18 Feb 2026
President and COO
Sold after exercise
2,200
$28.46
$62.61K

What was left out

Form 4 filings counted 60
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 22
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 10,726,209
History held since 28 Oct 2024